BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 27278654)

  • 1. Enhanced loading regimen of teicoplanin is necessary to achieve therapeutic pharmacokinetics levels for the improvement of clinical outcomes in patients with renal dysfunction.
    Ueda T; Takesue Y; Nakajima K; Ichiki K; Doita A; Wada Y; Tsuchida T; Takahashi Y; Ishihara M; Ikeuchi H; Uchino M; Kimura T
    Eur J Clin Microbiol Infect Dis; 2016 Sep; 35(9):1501-9. PubMed ID: 27278654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 μg/mL using a regimen of 12 mg/kg for five doses within the initial 3 days.
    Ueda T; Takesue Y; Nakajima K; Ichiki K; Ishikawa K; Takai Y; Yamada K; Tsuchida T; Otani N; Takahashi Y; Ishihara M; Takubo S; Ikeuchi H; Uchino M; Kimura T
    BMC Pharmacol Toxicol; 2020 Jul; 21(1):50. PubMed ID: 32641110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose regimen to achieve novel target trough concentration in teicoplanin.
    Ueda T; Takesue Y; Nakajima K; Ichki K; Wada Y; Komatsu M; Tsuchida T; Takahashi Y; Ishihara M; Kimura T; Uchino M; Ikeuchi H
    J Infect Chemother; 2014 Jan; 20(1):43-7. PubMed ID: 24462424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal trough concentration of teicoplanin for the treatment of methicillin-resistant Staphylococcus aureus infection: A systematic review and meta-analysis.
    Hanai Y; Takahashi Y; Niwa T; Mayumi T; Hamada Y; Kimura T; Matsumoto K; Fujii S; Takesue Y
    J Clin Pharm Ther; 2021 Jun; 46(3):622-632. PubMed ID: 33547647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of teicoplanin dosing designs to achieve a new target trough concentration.
    Ueda T; Takesue Y; Nakajima K; Ichki K; Wada Y; Tsuchida T; Takahashi Y; Ishihara M; Tatsumi S; Kimura T; Ikeuchi H; Uchino M
    J Infect Chemother; 2012 Jun; 18(3):296-302. PubMed ID: 22065089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal teicoplanin loading regimen to rapidly achieve target trough plasma concentration in critically ill patients.
    Li H; Gao L; Zhou L; Wang Y; Li Q; Wang J; Chen T; Zhang Y; Wang T; Shi Q
    Basic Clin Pharmacol Toxicol; 2020 Mar; 126(3):277-288. PubMed ID: 31608579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teicoplanin use in adult patients with haematological malignancy: Exploring relationships between dose, trough concentrations, efficacy and nephrotoxicity.
    Byrne CJ; Egan S; Fennell JP; O'Byrne P; Enright H; Deasy E; Ryder SA; D'Arcy DM; McHugh J
    Int J Antimicrob Agents; 2015 Oct; 46(4):406-12. PubMed ID: 26228465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of individual adjustment of initial loading dosage of teicoplanin based on population pharmacokinetics.
    Niwa T; Imanishi Y; Ohmori T; Matsuura K; Murakami N; Itoh Y
    Int J Antimicrob Agents; 2010 May; 35(5):507-10. PubMed ID: 20185275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of factors associated with the achievement of an optimal teicoplanin trough concentration
.
    Takechi K; Yanagawa H; Zamami Y; Ishizawa K; Tanaka A; Araki H
    Int J Clin Pharmacol Ther; 2017 Aug; 55(8):672-677. PubMed ID: 28655381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of teicoplanin concentrations and safety analysis in neonates.
    Yamada T; Kubota T; Nakamura M; Ochiai M; Yonezawa M; Yano T; Kawashiri T; Egashira N; Hara T; Masuda S
    Int J Antimicrob Agents; 2014 Nov; 44(5):458-62. PubMed ID: 25218156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced loading dose of teicoplanin for three days is required to achieve a target trough concentration of 20 μg/mL in patients receiving continuous venovenous haemodiafiltration with a low flow rate.
    Ueda T; Takesue Y; Nakajima K; Ichiki K; Ishikawa K; Yamada K; Tsuchida T; Otani N; Ide T; Takeda K; Nishi S; Takahashi Y; Ishihara M; Takubo S; Ikeuchi H; Uchino M; Kimura T
    J Infect Chemother; 2022 Feb; 28(2):232-237. PubMed ID: 34844858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the optimal dose of teicoplanin with therapeutic drug monitoring: not too high for adverse event, not too low for treatment efficacy.
    Kim SH; Kang CI; Huh K; Cho SY; Chung DR; Lee SY; Kim YJ; Peck KR
    Eur J Clin Microbiol Infect Dis; 2019 Nov; 38(11):2113-2120. PubMed ID: 31372903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recommended initial loading dose of teicoplanin, established by therapeutic drug monitoring, and outcome in terms of optimal trough level.
    Sato M; Chida K; Suda T; Muramatsu H; Suzuki Y; Hashimoto H; Gemma H; Nakamura H
    J Infect Chemother; 2006 Aug; 12(4):185-9. PubMed ID: 16944256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of teicoplanin administered by subcutaneous or intravenous route and simulation of optimal loading dose regimen.
    Cazaubon Y; Venisse N; Mimoz O; Maire P; Ducher M; Bourguignon L; Goutelle S
    J Antimicrob Chemother; 2017 Oct; 72(10):2804-2812. PubMed ID: 29091222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective study of teicoplanin loading regimen that rapidly achieves target 15-30 μg/mL serum trough concentration.
    Kato H; Hamada Y; Hagihara M; Hirai J; Nishiyama N; Koizumi Y; Yamagishi Y; Matsuura K; Mikamo H
    J Infect Chemother; 2016 May; 22(5):308-13. PubMed ID: 26960579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of teicoplanin trough concentration target and appropriate total dose during the first 3 days: a retrospective study in patients with MRSA infections.
    Matsumoto K; Kanazawa N; Ikawa K; Fukamizu T; Shigemi A; Yaji K; Shimodozono Y; Morikawa N; Takeda Y; Yamada K
    J Infect Chemother; 2010 Jun; 16(3):193-9. PubMed ID: 20195882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simplified dosing regimens of teicoplanin for patient groups stratified by renal function and weight using Monte Carlo simulation.
    Yamada T; Nonaka T; Yano T; Kubota T; Egashira N; Kawashiri T; Oishi R
    Int J Antimicrob Agents; 2012 Oct; 40(4):344-8. PubMed ID: 22818770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal teicoplanin dosage regimens for methicillin-resistant Staphylococcus aureus infections in endocarditis patients and renal failure patients.
    Li N; Zhu L; Xu G; Ge T; Qi F; Li M
    J Chemother; 2017 Dec; 29(6):358-364. PubMed ID: 28587526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of initial loading procedure for teicoplanin in critically ill patients with severe infections.
    Matsumoto K; Kanazawa N; Watanabe E; Yokoyama Y; Fukamizu T; Shimodozono Y; Maeda C; Yasuda T; Kakihana Y; Ikawa K; Morikawa N; Takeda Y
    Biol Pharm Bull; 2013; 36(6):1024-6. PubMed ID: 23727923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Teicoplanin Trough Values After the Recommended Loading Dose in Children With Associated Safety Analysis.
    Yamada T; Kubota T; Yonezawa M; Nishio H; Kanno S; Yano T; Kobayashi D; Egashira N; Takada H; Hara T; Masuda S
    Pediatr Infect Dis J; 2017 Apr; 36(4):398-400. PubMed ID: 27977550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.